What is the story about?
What's Happening?
Dr. Keith Roach has addressed inquiries regarding the use of PCSK9 inhibitors as alternatives to statins for cholesterol management. PCSK9 inhibitors, such as Repatha and Praluent, are effective in lowering cholesterol and reducing heart attack risk in high-risk individuals. These drugs are administered via injection and are costly, making them less common as first-line treatments compared to statins, which have been used for decades. However, for individuals unable to take statins or other alternatives like bempedoic acid, PCSK9 inhibitors are considered a reasonable option. In cases of familial high cholesterol, combination therapy involving statins, PCSK9 inhibitors, and sometimes ezetimibe is frequently employed.
Why It's Important?
The discussion around PCSK9 inhibitors is significant as it offers an alternative for individuals who cannot tolerate statins, which are the standard treatment for high cholesterol. This is particularly relevant for patients with familial hypercholesterolemia, who often require aggressive treatment to manage their cholesterol levels. The availability of PCSK9 inhibitors provides a viable option for these patients, potentially reducing their risk of cardiovascular events. However, the high cost and injection-based administration of these drugs may limit their accessibility and widespread use, highlighting the need for continued research and development in cholesterol management therapies.
AI Generated Content
Do you find this article useful?
